World Health Organization, 2018

The objective of these guidelines from the World Health Organization (WHO) is to provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings.

The guidelines update the WHO Package of Essential Non-communicable Disease Interventions (WHO PEN) for primary care in low-resources settings recommendations for managing hyperglycaemia, reviewing several newer oral agents: dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) and thiazolidinediones (TZDs). The guidelines also present new recommendations on the selection of type of insulin for adults with type 1 diabetes and in adults with type 2 diabetes.

Related to point-of-care testing, the guide provides useful information related to patient preferences for reducing numbers of injections and resource requirements for different medicines related to increased needles and self-monitoring, for example.

The full publication can be accessed here.

COL-08890 10/2021

Nouvelles connexes


"-- SEO4AJAX --" "seo4ajax Access"

"-- SEO4AJAX --" "Init" {"hubsSlug":"mypocacademy","regionsSlug":"ww","languagesSlug":"fr","newsSlug":"who-guidelines-on-second-and-third-line-medicines-and-type-of-insulin-for-blood-glucose-control-in-diabetes"}

"-- SEO4AJAX --" "Normalization A" {"hubsSlug":"mypocacademy","regionsSlug":"ww","languagesSlug":"fr","newsSlug":"who-guidelines-on-second-and-third-line-medicines-and-type-of-insulin-for-blood-glucose-control-in-diabetes"} 200 ""

"-- SEO4AJAX --" "Normalization B" {"hubsSlug":"mypocacademy","regionsSlug":"ww","languagesSlug":"fr","newsSlug":"who-guidelines-on-second-and-third-line-medicines-and-type-of-insulin-for-blood-glucose-control-in-diabetes"} 200 ""

"-- SEO4AJAX --" "Timeout: " 5 " seconds"

"-- SEO4AJAX --" "$window.onCaptureReady Called" 200 ""

"-- SEO4AJAX --" "Bugsnag Called"